Runnymede Capital Advisors Inc. Acquires New Position in Novo Nordisk A/S $NVO

Runnymede Capital Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, Holdings Channel.com reports. The fund acquired 24,604 shares of the company’s stock, valued at approximately $1,252,000.

Other large investors also recently bought and sold shares of the company. Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares during the last quarter. Invesco Ltd. lifted its position in shares of Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after buying an additional 87,467 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,891 shares of the company’s stock valued at $338,000 after buying an additional 511 shares during the period. Institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi‑month subscription program for Wegovy to lower out‑of‑pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self‑pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross‑trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP‑1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug‑pricing body for heart‑disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium‑term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once‑a‑week insulin work and early triple‑agonist studies — supports longer‑term growth optionality beyond current GLP‑1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP‑1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low‑cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re‑pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near‑term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NVO shares. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a report on Tuesday, March 10th. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $36.92 on Monday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm has a market cap of $164.86 billion, a P/E ratio of 10.64, a PEG ratio of 8.75 and a beta of 0.73. The stock has a fifty day moving average price of $43.43 and a two-hundred day moving average price of $49.74. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s payout ratio is 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.